OrbiMed Advisors member companies SmartZyme BioPharma and Hemoshear Therapeutics today announced a strategic agreement to develop new protein therapeutics for the treatment of rare metabolic diseases. To support the collaboration, SmartZyme has divested its protein engineering platform into a new company, Carnot BioSciences, which will be led by a team reorganized by former Synageva and Alexion scientists and managers. After the divestiture, SmartZyme will focus on driving its core assets, a next-generation glucose-sensing enzyme designed to significantly reduce the cost and manufacturing of continuous blood glucose monitors used in patients with type 1 diabetes and insulin-dependent type 2 diabetes. Difficulty.
HemoShear proprietary drug discovery platform REVEAL-TX TM HemoShear to create the best in class, human disease model biologically meaningful to reveal the underlying disease mechanisms, these discoveries into drug candidates, and the selection of promising candidates for the treatment of patients drug.
Under the terms of the agreement, Carnot will use its expertise in the evolution of directed enzymes to alter specific human enzymes recognized by HemoShear to treat certain undisclosed inborneral metabolic defects, including enzyme defects and mutations. These defects prevent the body system from properly converting food into energy, leading to a variety of symptoms, many of which can lead to death.
Dr. Christopher Shepard, General Manager and CEO of Smartzyme BioPharma, will serve as interim general manager and CEO of Carnot BioSciences. Synageva BioPharma and Alexion Pharmaceuticals, former vice president of research and vice president of expression and bioanalysis, Mark Leavitt, PhD will serve as Chief Scientific Officer of Carnot and will work with former Synageva/Alexion staff with clinical development, regulatory affairs and market entry areas Expertise.
Dr. Shepard said: "We look forward to working with the HemoShear team to leverage their REVEAL-TXTM platform to explore disease pathways, select the best drug targets, and find promising drug candidates. The agreement provides a basis for addressing Some of the most daunting challenges in the biochemical field of contemporary protein therapeutics."
Dr. Brian Wamhoff, co-founder and innovation director at HemoShear, said: "Carnot BioSciences' protein engineering technology is a valuable platform for the development of new protein therapeutics. Our research shows that specific enzyme modifications can improve the body's ability to attenuate these toxins. Destructive diseases are related. We believe that the application of Carnot's directed evolution to generate these new therapeutic drugs will ultimately provide a better outcome for patients."
Dr. Leavitt said: “Carnot and HemoShear have unique and complementary scientific expertise to work together to create a powerful synergy to discover promising new drug candidates for the treatment of devastating and life-threatening metabolic diseases. Demand is far from being met, and we look forward to pushing drug candidates into human clinical trials."
Carnot and HemoShear will work together to discover drug candidates, each of which is responsible for bringing specific projects to the clinic. The financial terms of the agreement were not disclosed.
Freeze-dried powder is a sterile powder injection obtained by freezing the liquid medicine into a solid state in a sterile environment, and subliming and drying the water in a vacuum. Freeze-dried powder is composed of a bottle of high-purity and high-active biological protein freeze-dried powder and a high-purity liquid essence. When using, it needs to be connected with a patented vacuum to reconstitute the freeze-dried powder and the essence to activate the biological protein activity.
Freeze Dried Fruit Powder,Strawberry Powder,Freeze Dried Powder,Raspberry Powder
YT(Xi'an) Biochem Co., Ltd. , https://www.ytherblifes.com